EUVIMEDEUVIMED entdecken
Crossref

Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer’s disease

Vijay R Varma, Yang An, Przemek R Kac, Murat Bilgel, Abhay Moghekar, Tina Loeffler, David Amschl, Magdalena Daurer, Manuela Prokesch, Juan Troncoso, Kaj Blennow, Henrik Zetterberg und 4 weitere

Med · 2025

DOI: 10.1016/j.medj.2025.100724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Med, 2025. Verfasst von Vijay R Varma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Hea…. Hauptthemen laut MEDLINE: Alzheimer Disease, Glial Fibrillary Acidic Protein, Gliosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Defining the progression of blood biomarkers in Alzheimer's disease (AD) is essential for targeting treatments in patients most likely to benefit from early intervention. We delineated the temporal ordering of blood biomarkers a decade prior to the onset of AD, explored associations with AD brain pathology, and examined the relationship between reactive astrocytosis in the brain and plasma in a transgenic mouse model. METHODS: We analyzed plasma blood biomarkers using the Quanterix HD-X instrument in case-control and postmortem cohorts from the Baltimore Longitudinal Study on Aging (BLSA). We assessed plasma and cortical reactive astrocytosis, measured by glial fibrillary acidic protein (GFAP), in 5xFAD transgenic and wild-type mice. FINDINGS: In AD-converters (N = 158, 377 samples), higher plasma GFAP levels are observed 10 years prior to the onset of cognitive impairment due to AD compared with individuals who remain cognitively unimpaired (N = 160, 379 samples). Plasma GFAP levels are highest in neuropathologically confirmed AD, intermediate in asymptomatic AD, and lowest in cognitively unimpaired and associated with severity of neuritic plaques and neurofibrillary tangles. GFAP-labeled immunoreactive astrocytes in the cortex of 3- and 7-month-old 5xFAD transgenic mice increased relative to wild-type mice and higher blood GFAP concentration was associated with more GFAP-expressing astrocytes. CONCLUSIONS: Reactive astrocytosis, assessed by elevated GFAP levels, is an early event in the progression of blood biomarker changes in preclinical AD, may be an early marker of AD pathogenesis, and a promising therapeutic target. FUNDING: Intramural Research Program, NIA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseGlial Fibrillary Acidic ProteinGliosisBiomarkersAnimalsHumansDisease ProgressionMice, TransgenicMiceMaleFemaleLongitudinal StudiesAgedDisease Models, AnimalCase-Control StudiesAged, 80 and overAstrocytesBrain

Stichwörter der Autor:innen

Translation to patientsreactive astrocytosis, glial fibrillary acidic protein, Alzheimer's disease, bl…

Substanzen

BiomarkersGlial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Health (NIH), Baltimore, MD, USA.
  • Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Health (NIH), Baltimore, MD, USA.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
  • Scantox Neuro GmbH, Parkring 12, Grambach 8074, Austria.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Varma, V. R., An, Y., Kac, P. R., Bilgel, M., Moghekar, A., Loeffler, T., Amschl, D., Daurer, M., Prokesch, M., Troncoso, J., Blennow, K., Zetterberg, H., Ashton, N. J., Ferrucci, L., Resnick, S. M., & Thambisetty, M. (2025). Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer’s disease. Med. https://doi.org/10.1016/j.medj.2025.100724

Vancouver

Varma VR, An Y, Kac PR, Bilgel M, Moghekar A, Loeffler T, et al. Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer’s disease. Med. 2025. doi:10.1016/j.medj.2025.100724

BibTeX
@article{Varma2025,
  author = {Varma, Vijay R and An, Yang and Kac, Przemek R and Bilgel, Murat and Moghekar, Abhay and Loeffler, Tina and Amschl, David and Daurer, Magdalena and Prokesch, Manuela and Troncoso, Juan and Blennow, Kaj and Zetterberg, Henrik and Ashton, Nicholas J and Ferrucci, Luigi and Resnick, Susan M and Thambisetty, Madhav},
  title = {Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer’s disease},
  journal = {Med},
  year = {2025},
  doi = {10.1016/j.medj.2025.100724}
}
Kostenlos starten →